MX2022016341A - Formas farmaceuticas de maleato de acalabrutinib. - Google Patents

Formas farmaceuticas de maleato de acalabrutinib.

Info

Publication number
MX2022016341A
MX2022016341A MX2022016341A MX2022016341A MX2022016341A MX 2022016341 A MX2022016341 A MX 2022016341A MX 2022016341 A MX2022016341 A MX 2022016341A MX 2022016341 A MX2022016341 A MX 2022016341A MX 2022016341 A MX2022016341 A MX 2022016341A
Authority
MX
Mexico
Prior art keywords
dosage forms
pharmaceutical dosage
acalabrutinib
methods
maleate
Prior art date
Application number
MX2022016341A
Other languages
English (en)
Inventor
Michael Golden
Andrew Robbins
Paul Bethel
John Blyth
Steve Cosgrove
James Mann
Xavier Jacques Henri Pepin
David Simpson
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MX2022016341A publication Critical patent/MX2022016341A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación se refiere, en general, a: (a) formas farmacéuticas sólidas que comprenden maleato de acalabrutinib; (b) métodos de uso de dichas formas farmacéuticas para tratar neoplasias de linfocitos B y/u otras afecciones; (c) kits que comprenden dichas formas farmacéuticas y, opcionalmente, una segunda forma farmacéutica que comprende otro agente terapéutico; (d) métodos de preparación de dichas formas farmacéuticas; y (e) formas farmacéuticas preparadas mediante dichos métodos.
MX2022016341A 2020-06-19 2021-06-18 Formas farmaceuticas de maleato de acalabrutinib. MX2022016341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063041197P 2020-06-19 2020-06-19
PCT/EP2021/066629 WO2021255246A1 (en) 2020-06-19 2021-06-18 Acalabrutinib maleate dosage forms

Publications (1)

Publication Number Publication Date
MX2022016341A true MX2022016341A (es) 2023-01-24

Family

ID=76829497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016341A MX2022016341A (es) 2020-06-19 2021-06-18 Formas farmaceuticas de maleato de acalabrutinib.

Country Status (19)

Country Link
US (1) US20230226049A1 (es)
EP (1) EP4167968A1 (es)
JP (1) JP2023531606A (es)
KR (1) KR20230027201A (es)
CN (1) CN115916161A (es)
AR (1) AR122681A1 (es)
AU (2) AU2021291437B2 (es)
BR (1) BR112022025611A2 (es)
CA (1) CA3186141A1 (es)
CL (1) CL2022003620A1 (es)
CO (1) CO2023000536A2 (es)
CR (1) CR20230018A (es)
DO (1) DOP2022000287A (es)
IL (1) IL298872A (es)
MX (1) MX2022016341A (es)
PE (1) PE20230992A1 (es)
TW (1) TW202200145A (es)
UY (1) UY39288A (es)
WO (1) WO2021255246A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024084496A1 (en) * 2022-10-17 2024-04-25 Natco Pharma Limited Pharmaceutical compositions comprising acalabrutinib maleate
WO2024164066A1 (en) * 2023-02-09 2024-08-15 Apotex Inc Crystalline forms of acalabrutinib maleate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2757882T5 (es) * 2009-11-09 2023-05-10 Wyeth Llc Formulaciones de comprimidos de maleato de neratinib
LT2734522T (lt) 2011-07-19 2019-02-11 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai
EP2572703A1 (en) * 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
BR112017025398A2 (pt) * 2015-06-04 2018-08-07 Pfizer Inc. formas de dosagem sólidas de palbociclib
AU2016286548B2 (en) 2015-07-02 2020-12-10 Acerta Pharma B.V. Solid forms and formulations of (S)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
US10899770B2 (en) * 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
IL312413A (en) 2018-08-29 2024-06-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-inol)-pyrrolidine-2-YL]imidazo[1,5-A]-pyrazine-1-YL}N- (pyridine-2-YL)-benzamide

Also Published As

Publication number Publication date
EP4167968A1 (en) 2023-04-26
JP2023531606A (ja) 2023-07-25
UY39288A (es) 2022-01-31
TW202200145A (zh) 2022-01-01
AU2021291437B2 (en) 2024-07-04
AU2021291437A1 (en) 2023-02-16
CA3186141A1 (en) 2021-12-23
PE20230992A1 (es) 2023-06-23
KR20230027201A (ko) 2023-02-27
AR122681A1 (es) 2022-09-28
AU2024204906A1 (en) 2024-08-01
CO2023000536A2 (es) 2023-01-26
CN115916161A (zh) 2023-04-04
US20230226049A1 (en) 2023-07-20
IL298872A (en) 2023-02-01
WO2021255246A1 (en) 2021-12-23
BR112022025611A2 (pt) 2023-01-03
CL2022003620A1 (es) 2023-05-05
DOP2022000287A (es) 2023-03-15
CR20230018A (es) 2023-04-11

Similar Documents

Publication Publication Date Title
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
EP1933833B8 (en) Therapy for the treatment of overactive bladder
CR20230018A (es) Formas farmacéuticas de maleato de acalabrutinib
SI1778680T1 (sl) Spirociklični cikloheksanski derivati
WO2016133903A3 (en) Combination therapy for cancer treatment
RU2017134443A (ru) Способ лечения с применением традипитанта
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
HK1071310A1 (en) Combination therapy for the treatment of cancer
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
IN2012DN03172A (es)
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
ZA202308118B (en) Cdk inhibitor
ZA202400595B (en) Spirocyclic compounds
PH12021550557A1 (en) Furo[3,4-b]pyrrole-containing btk inhibitor
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
MX2022012001A (es) Tratamiento preventivo de la migra?a.
WO2023069514A9 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
NZ584968A (en) Novel antiretroviral combination comprising ritonavir and atazanavir